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Background: Aortoenteric fistula (AEF) is a critical clinical condition, which may present with gastrointestinal hemor-
rhage, with or without signs of sepsis. Conventional open surgical repair is associated with high morbidity and mortality.
Endovascular stent graft repair has been attempted, but recurrent infection remains of major concern. We conducted a
systematic review to assess potential factors associated with poor outcome after endovascular treatment.
Methods: The English literature was searched using the MEDLINE electronic database up to April 2008. All studies
reporting on the primary management of primary or secondary AEFwith endovascular stent graft repair were considered.
Results: Data were extracted from 33 reports that included 41 patients and were entered in the final analysis.
Persistent/recurrent/new infection or recurrent hemorrhage developed in 44% of the patients, after a mean follow-up
period of 13 months (range, 0.13-36). Secondary, as compared to primary, AEF had an almost threefold increased risk
of persistent/recurrent infection. Evidence of sepsis preoperatively was found to be a factor indicating unfavorable
outcome (P < .05). Persistent/recurrent/new infection after treatment was associated with worse 30-day and overall
survival compared with those who did not develop sepsis (P < .05).
Conclusion: Endovascular stent graft repair of AEF was associated with a high incidence of infection or recurrent bleeding
postoperatively. Evidence of sepsis preoperatively was indicating poor outcome. (J Vasc Surg 2009;49:782-9.)Aortoenteric fistula (AEF), defined as an abnormal
communication between the aortic and bowel lumen, is a
devastating clinical condition necessitating immediate sur-
gical intervention. It can occur either in the setting of a
primary process involving the aorta and the gastrointestinal
tract or, more commonly, secondary to previous aortic
reconstructive surgery. The condition may manifest with
gastrointestinal hemorrhage alone or in combination with
signs of sepsis. Despite its rarity, represented by an inci-
dence in the range of 0.02 and 0.07% in autopsy studies for
primary AEF and of less than 1% in patients after abdominal
aortic reconstruction, AEF represents a significant clinical
entity associated with high morbidity and mortality.1-3
Conventional surgical repair consists of extra-anatomic by-
pass grafting and aortic ligation for primary AEF, or in the
case of secondary AEF, graft excision accomplished with
extra-anatomic bypass or in situ aortic reconstruction.
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782These surgical procedures undertaken in a critically ill,
severely exsanguinated and septic patient are associated
with high operative morbidity and mortality rates.1,4-6
In view of these observations, less invasive endovascular
aortic procedures, associated with less operative trauma and
stress for the patient, have opened an alternative treatment
option for this devastating complication. There are several
studies reporting successful management of AEF with en-
dovascular techniques (Table I) providing encouraging
results. However, skepticism exists whether endovascular
management of AEF should merely be a “bridge” to open
surgery or may constitute a permanent solution, because it
remains of serious concern the placement of a prosthetic
material in an already infected field.
We therefore conducted a systematic review of the
literature and analyzed the reported cases to determine the
factors associated with poor outcome and persistent infec-
tion after endovascular treatment of AEF.
METHODS
Search strategy. An electronic literature search of
public domain databases (MEDLINE) was performed us-
ing a Web-based search engine (PubMed) for articles pub-
lished between January 1990 and April 2008. The litera-
ture search was confined to studies published in English.
The keywords aortoenteric fistula; aorto-duodenal fistula,
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Study Year Age Gender P/S Site Cause of primary AEF Cancer
Leonhardt et al16 2008 82 M S AA NA No
Taylor et al17 2007 69 F S TA NA No
Chisci et al18 2007 56 M S AA NA No
Papacharalambous et al19 2007 70 M P AA AAA No
Barleben et al20 2007 54 M P AA Traumatic aortic dissection No
Deshmukh et al21 2007 46 M S TA NA No
Broutzos et al22 2007 85 M S AA NA No
Metz et al23 2006 31 M P TA Aortic trauma due to ingestion of foreign body No
Ikeda et al24 2006 64 M P TA Aortic wall invasion by esophageal carcinoma Yes
Ting et al25 2006 87 M P TA NR No
59 M P TA Esophageal carcinoma-chemoirradiation Yes
Verhey et al26 2006 66 F P AA Eroding duodenal stent Yes
Shapiro et al27 2006 83 F S AA NA No
Kotsis et al28 2006 53 M S AA NA No
Biancari et al29 2006 58 M S AA NA No
Suzuki et al30 2005 71 M S AA NA No
Assink et al31 2005 32 M P TA Aortic trauma due to ingestion of foreign body No
Gonzalez-Fajardo et al32 2005 75 M S AA NA No
68 M P TA Mycotic thoracic aortic aneurysm No
Nishibe et al33 2004 71 F P TA Thoracic aortic aneurysm No
Mok et al34 2004 67 M P TA Esophageal carcinoma-esophagectomy Yes
Dieter et al35 2002 64 M S AA NA Yes
Tomlinson et al36 2002 90 M S AA NA No
Finch et al37 2002 71 F P AA Metastatic ovarian carcinoma-peri-aortic
adenopathy
Yes
Leobon et al38 2002 61 M S TA NA No
80 M P TA Thoracic aortic aneurysm No
van Doorn et al39 2002 66 F P TA Mycotic thoracic aortic aneurysm Yes
D’Ancona et al40 2002 78 F P TA Aortic ulcer No
Burks et al41 2001 73 M S AA NA No
82 M P AA AAA No
92 M S AA NA No
73 F S AA NA No
76 M S TA NA No
88 M S AA NA No
Bond et al42 2001 58 F S TA NA No
Chuter et al43 2000 76 M S AA NA No
Grabs et al44 2000 67 M S AA NA No
Kato et al45 2000 59 M P TA Esophageal carcinoma-radiotherapy Yes
Schlensak et al46 2000 64 M S AA NA No
Deshpande et al47 1999 67 M S AA NA Yes
Oliva et al48 1997 40 M P TA Esophageal carcinoma-esophagectomy Yes
Hemodynamic
instability Infection Type of stent graft
Fistula
occlusion
Adjunctive
procedure
Lifelong
antibiotics
Yes Yes Thoracic endoprosthesis (TAG, Gore) No Yes Yes
No Yes Straight sent graft with 1 extension No No No
No Yes Tube graft endoprosthesis (Talent, Medtronic) No No No
No Yes Bifurcated aortoiliac stent graft (Lifepath) No No Yes
Yes No 2 aortic extension cuffs (Excluder, Gore) No No No
No No Aortic stent graft (Zenith, Cook) No No No
Yes No Bifurcated stent graft (Excluder, Gore) No No No
Yes Yes Thoracic aortic stent graft (TAG, Gore) Yes Yes No
Yes No Gianturco Z-stent graft (Cook) covered with a Dacron graft Yes Yes No
Yes Yes AneuRx No No Yes
No Yes Zenith No No Yes
Yes No Aortic cuff (AneuRx, Medtronic) No No Yes
Yes Yes Bifurcated stent graft (Excluder, Gore) No No Yes
Yes No Aorto-uni-iliac stent graft (Zenith, Cook), F-F bypass No Yes Yes
No Yes Stent graft (TAG, Gore) Yes Yes No
No No Gianturco Z-stent graft (Cook) covered with woven graft No No No
Yes No Stent graft (Talent, Medtronic) Yes Yes No
Yes No Tube stent graft (Talent, Medtronic) Yes Yes No
Yes Yes 2 Talent stent grafts No No Yes
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Hemodynamic
instability Infection Type of stent graft
Fistula
occlusion
Adjunctive
procedure
Lifelong
antibiotics
No No Gianturco Z-stent graft (Cook) covered with polyester tube No No No
Yes Yes Thoracic stent graft (Talent, Medtronic) Yes Yes Yes
No Yes Aortoiliac stent graft No No Yes
No No 2 Talent stent grafts No No No
Yes No AneuRx stent graft Yes Yes No
No No Talent stent graft No No No
No No Talent stent graft No No No
No Yes Thoracic stent graft (Excluder, Gore) Yes Yes No
No No 2 Talent stent grafts No No No
Yes Yes Aorto-uni-iliac stent graft No Yes Yes
No No Talent Dacron tube endograft No No Yes
No No Bifurcated stent graft (Excluder, Gore) No No Yes
No No Aorto-uni-iliac stent graft No No Yes
Yes Yes Talent Dacron tube endograft No No Yes
Yes Yes Talent Dacron tube endograft No Yes Yes
Yes No AneuRx stent graft (Medtronic) No No No
No No 2 Gianturco Z-stent grafts (Cook) No No No
No Yes AneuRx extender cuff (Medtronic) No No No
Yes No Z-stent (Cook) covered with PTFE (Impra) No Yes Yes
Yes Yes Bifurcated stent graft (Mintec, Stentor) No No No
Yes No Vanguard endovascular tube graft No No Yes
Yes No Palmaz stent graft covered with Dacron graft No No No
Complications Follow-up Mortality Reason of death
Persistent/
recurrent/new infection
Recurrent
bleeding
Bleeding 21 d 25 d MOSF Yes Yes
Persistent sepsis 4 d NA NA Yes No
Sepsis, GI hemorrhage 4 m NA NA Yes Yes
No 21 m NA NA No No
No 7 m NA NA No No
Sepsis 18 m NA NA Yes No
Persistent sepsis 12 m NA NA Yes No
No 8 m NA NA No No
No 6 m NA NA No No
Persistent sepsis 3 m 3 m Sepsis Yes No
Persistent sepsis, recurrent bleeding 3 m 3 m Sepsis, recurrent bleeding Yes Yes
No 6 m NA NA No No
Infection of R fem. interposition graft 14 m NA NA No No
Postoperative fever 18 m NA NA No No
Fluid collection/increased CRP 8 m NA NA Yes No
No 20 m NA NA No No
No 13 m NA NA No No
Persistent sepsis 2 m 2 m Aortic rupture Yes Yes
Persistent sepsis 9 d 9 d Aortic rupture Yes Yes
No 36 m NA NA No No
No 14 m NA NA No No
Sepsis 3 m NA NA Yes No
No 14 m 14 m MI No No
No NA Carcinoma No No
R ilio-femoral bypass, L CFA embolectomy 36 m NA NA No No
Leakage, mediastinitis 25 m 25 m Sepsis Yes No
Mediastinal fluid collection 24 m NA NA Yes No
No 6 m NA NA No No
No 18 m 18 m CVA Yes No
Persistent sepsis 13 m 13 m MI No No
No 34 m NA NA No No
No 23 m NA NA No No
Persistent sepsis, MOSF 26 d 26 d MOSF Yes No
Persistent sepsis, ATN 11 m 11 m MI Yes No
No 33 m NA NA No No
Persistent sepsis 8 m NA NA Yes No
No 18 m NA NA No No
No 4.5 m 4.5 m Pneumonia No No
VA, c
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vascular or stent were used to extract the relevant abstracts.
The references of the retrieved articles were also manually
searched for any additional relevant articles. The literature
search; study selection; and data extraction from the rele-
vant studies were performed by two independent authors
(G.A.A.; S.A.A.).
Eligibility studies, data abstraction, and definitions
of parameters and outcome endpoints. Studies consid-
ered for inclusion fulfilled the following criteria: (1) to
report on the primary management of AEF with endovas-
cular stent graft techniques, (2) to report on the presenting
symptoms of the AEF, and (3) to report on the outcome
after endovascular treatment of the AEF. All studies report-
ing on communication between the gastrointestinal tract
and arteries other than the aorta were excluded.
Data abstracted and parameters considered for further
analysis were the following: patient age and gender, pri-
mary or secondary AEF, site of AEF, the cause of primary
AEF, presence of hemodynamic instability, and signs and
symptoms of infection preoperatively, type of stent graft
used, fistula occlusion, adjunctive procedure, life-long an-
tibiotics, complications, duration of follow-up, mortality,
reason of death, persistent, recurrent, or new infection, and
recurrent bleeding after treatment (Table I). Hemody-
namic instability was considered if one or more of the
following features were reported in the text of the articles:
(1) systolic blood pressure less than 100 mm Hg plus
tachycardia, (2) profound hypotension, (3) requirement of
massive blood transfusion, and (4) massive hemorrhage.
Clinical evidence of infection preoperatively was considered
if any one of the following was reported: (1) fever, (2) white
blood cell count more than 10,000/dL, (3) perigraft fluid
or air on computed tomography (CT). If none of the above
features was reported in the text, it was presumed that there
was no hemodynamic instability or no clinical evidence of
infection preoperatively.
The endpoints of outcome were defined as either
healed or treatment failure, depending on: (1) the presence
or absence of documented signs and symptoms of recur-
rent, persistent, or new infection attributed to aortic stent
graft and (2) the presence or absence of recurrent bleeding,
up to the end of the follow-up period for each individual
patient.
Statistical analysis. We analyzed the data by using
Table I. Continued.
Complications Follow-up Mortal
Recurrent fistula 5 m NA
No 6 m NA
No 13 m NA
M, male; F, female; P, primary; S, secondary; AEF, aorto-enteric fistula AA,
aortic aneurysm; d, day; m, month; MOSF, multiple organ system failure; C
common femoral artery; NA, not applicable; NR, not reported.SPSS 15 for Windows (SPSS Inc, Chicago, Ill). The explor-atory data analyses checked the distribution of values, and
for each variable the proportion (percentage) of the total
number of patients in the healed and persistent/recurrent/
new infection group was calculated. The 2 test was used to
evaluate the differences between the healed and the persistent/
recurrent/new infection group for categorical variables. All
statistical tests were two tailed, and a P value  .05 was
considered statistically significant. The relationship be-
tween potential predictors and outcome was assessed using
the odds ratio (ORs) and 95% confidence intervals (CI).
The cumulative survival curve was calculated by using the
Kaplan-Meier method.
RESULTS
Literature search results. Our search of the medical
literature identified 42 studies, reporting on the endovas-
cular stent graft repair of acute AEF, which were thor-
oughly reviewed. They were either case reports or small
case series. Five studies were excluded due to inadequate
individual patient data,7-11 one due to reporting on the
endovascular management of an ilio-enteric fistula,12 and
another three due to reporting on the secondary rather
than primary endovascular management of AEF.13-15 Data
were extracted from 33 reports that included 41 patients
suffering from AEF, who were managed with endovascular
stent graft repair, and were entered in the final analysis.16-48
Patient characteristics. The main characteristics of
the patients are summarized in Table I. The study group
consisted of 32 males and 9 females with a mean age of 68
years (range, 31-92 years), presenting with AEF primarily
managed with endovascular stent graft placement. The
mean follow-up period for these patients was 13 months
(range, 0.13-36).
Eighteen (43.90%) of the AEF were primary and 23
(56.10%) were secondary, the pathologic lesion was located
in the abdominal aorta in 23 cases (56.10%) and in the
thoracic aorta in 18 cases (43.90%). Of the 23 AEF located
in the abdominal aorta only 5 (22%) were primary and 18
(78%) were secondary, whereas of the 18 AEF located in
the thoracic aorta 13 (72%) were primary and only 5 (28%)
were secondary. It was, therefore, found that thoracic aortic
AEF were nine times more likely to be primary rather than
secondary as compared with abdominal aortic AEF (P 
.001; OR, 9.360; 95% CI, 2.239-39.121). The causes of
primary AEFwere aortic aneurysm-related in 6 cases (33%),
Reason of death
Persistent/
recurrent/new infection
Recurrent
bleeding
NA Yes Yes
NA No No
NA No No
inal aorta; TA, thoracic aorta; AEF, aortoenteric fistula; AAA, abdominal
erebrovascular accident; MI, myocardial infarction; R, right; L, left; CFA,ity
abdomgastrointestinal tract carcinoma-related in another 6 cases
omina
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ulcer in 1 case (6%), and secondary to an eroding duodenal
stent in another case (6%) (Table I). Twenty-two of these
patients (53.66%) had symptoms or signs of hemodynamic
instability, as defined in the METHODS section, either on
admission or during diagnostic workup, and were urgently
transferred to the operating room. Clinical, laboratory, or
imaging evidence of infection prior to surgical intervention,
as defined in the METHODS section, was present in
43.90% of patients (18 patients). Imaging confirmation of
the AEF was either endoscopic, with upper gastrointestinal
endoscopy, or radiological, with angiography or CT, in all
cases.
The types of stent graft used for the endovascular repair
of the AEF are shown in Table I. No conclusions on the
associations between the type and configuration of the
stent graft devises and the outcome can be drawn, because
of the great variety of the stent grafts used at different
anatomical sites. In 8 patients (19.51%) the endovascular
management of the AEF was accompanied by repair of the
contributing part of the gastrointestinal tract (fistula occlu-
sion) with endoscopic, endovascular, or open surgical pro-
cedures; in one case a fibrin sealant was injected in the
fistula tract endoscopically,34 in another case the fistula was
catheterized under angiographic control and was injected
with N-butyl 2-cyanocrylate,37 and in the remaining six
cases the communication between the aorta and the bowel
lumen was interrupted through a laparotomy or thoracot-
omy.23,24,29,31,32,39 Adjunctive procedures other than fis-
tula occlusion included diverting iliostomy,41 CT-guided
drainage of aortic sac,41 psoas abscess drainage,16 coil-
embolization of the aortic bifurcation,28 and balloon dila-
tation of the stent graft to treat leakage.45 Life-long anti-
biotic therapy postoperatively was reported to have been
given to 18 patients (43.90%). Of interest is that of the 23
patients who were not presumed to have graft-related in-
fection preoperatively, 7 patients (30%) were given life-long
antibiotic therapy. During the follow-up period, 21 pa-
tients (51.22%) developed complications, the most serious
Table II. Analysis of potent predictors of persistent/recur
Variable
Persistent/recurrent/new
infection n  18 (%)
Age 70 years 9 (50.00%)
Male sex 16 (88.89%)
Primary/secondary AEF 5/13 (27.78%/72.22%) 13
AA/TA 10/8 (55.56%/44.44%) 13
Cancer 3 (16.67%)
Hemodynamic instability 9 (50.00%)
Signs of infection 13 (72.22%)
Fistula occlusion 3 (16.67%)
Adjunctive procedure 6 (33.33%)
Life-long antibiotics 8 (44.44%)
Post-op complications 17 (94.44%)
30-day mortality 3 (16.67%)
OR, odds ratio; CI, confidence interval; AEF, aortoenteric fistula; AA, abdof which were either related to recurrent/persistent/newsepsis or recurrent bleeding (Table I). Twelve patients died
during the follow-up period (29.27%), in 7 of whom
(58.33%) this was due to septic complications.
Factors associated with persistent/recurrent infection.
The 41 patients were divided into two groups: one in-
cluded those who did not develop symptoms or signs of
graft-related infection or recurrent bleeding (healed group,
n  23), and the other included patients who developed
graft-related infection or bleeding during the follow-up
period (persistent/recurrent/new infection group, n 
18). The mean follow-up period for the healed and the
recurrent/persistent/new infection group was 17 (range,
4.5-35) and 9 (range, 0.13-25) months, respectively. Var-
ious parameters which were suggested to be associated with
the outcome after endovascular management of AEF were
analyzed (Table II). Our analysis showed that of the 18
patients who presented with infection, 13 patients (72.22%)
developed persistent or recurrent sepsis during the follow-up
period and 5 patients (21.74%) healed. On the other hand, of
the 23 patients who did not have evidence of infection preop-
eratively, 5 patients (21.74%) developed infection postoper-
atively and 18 patients (78.26%) healed. Univariate analysis
found that signs of infection preoperatively and complica-
tions developed at any time after endovascular treatment of
the AEF were factors associated with poor outcome (signs
of infection preoperatively: P  .001; OR, 9.360; 95% CI,
2.239-39.121, complications: P  .0001; OR, 80.750;
95% CI, 8.203-794.944).
Survival curves were plotted separately for the two
groups of patients (Fig 1). The log-rank test was used to
assess the difference in survival between the two groups,
comparing events occurring at all time points on the sur-
vival curve. It was found that the healed group had a
statistically significant difference in the survival times as
compared with the persistent/recurrent/new infection
group (P  .05). The standard error for estimated proba-
bility of 0.94 and 0.40 are 0.06 and 0.16, respectively, for
the infection group. The standard error for estimated sur-
vival probability of 0.96 and 0.82 are 0.04 and 0.10,
/new infection after endovascular management of AEF
led n  23 (%) P value OR (95% CI)
(39.13%) .486 1.556 (0.447-5.413)
(69.57%) .138 3.500 (0.628-19,496)
(56.52%/43.48%) .066 0.296 (0.079-1.108)
(56.52%/43.48%) .951 0.962 (0.278-3.331)
(30.43%) .308 0.457 (0.099-2.101)
(56.52%) .678 0.769 (0.223-2.654)
(21.74%) .001 9.360 (2.239-39.121)
(21.74%) .684 0.720 (0.147-3.520)
(30.43%) .843 1.143 (0.305-4.289)
(43.48%) .951 1.040 (0.300-3.603)
(17.39%) .000 80.750 (8.203-794.944)
(0.00%) .042 1.200 (0.976-1.475)
l aorta; TA, thoracic aorta.rent
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0respectively, for the healed group.
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AEF represents one of the most uncommon but devas-
tating clinical conditions a vascular surgeonmay encounter.
Despite progress in aortic surgery over the last decades, it is
often a lethal condition, associated with dismal results. The
physiological stress of massive hemorrhage along with that
of sepsis, in the presence of co-morbid medical conditions,
is magnified by a major operative procedure. The tradi-
tional management goals of AEF have been the control of
hemorrhage, control of sepsis, and maintenance of lower
limb perfusion. These are conventionally achieved with
major reconstructive open surgery, which is accompanied
with high morbidity and mortality rates.4-6
Endovascular techniques have emerged as another
therapeutic option for the management of AEF achieving
rapid control of bleeding with minimal insult, avoiding
intervention in a hostile abdomen, and eliminating the
complications associated with open surgical repair. How-
ever, it could be argued that only two of the three afore-
mentioned fundamental management goals of AEF can be
achieved with endovascular techniques, as the stent graft
can effectively and rapidly control bleeding and maintain
adequate distal perfusion, but the presence of aorto-enteric
communication serves as a nidus for continuing bacterial
growth and persistent infection. Therefore, placing a new
prosthetic material in an already or potentially infected
field, without eradicating the source of infection, creates
concerns about the long-term safety and efficacy of the
method.
The first reports of successful endovascular treatment of
AEF involving the abdominal and the thoracic aorta were
performed a decade ago by Deshpande et al47 and Oliva et
al,48 respectively, and were followed by several other re-
ports with contradictory results. Our systematic review of
the literature has found that persistent, recurrent, or new
Months
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Survival Functions
Fig. Kaplan-Meier curves displaying the cumulative survival prob-
ability following endovascular treatment of aorto-enteric fistula
(AEF), stratified by the presence or absence of persistent/recur-
rent/new infection.infection developed in 44% of the patients having under-gone endovascular repair of the AEF, after a mean follow-
up period of 13 months (range, 0.13-36). This figure most
likely represents the lowest possible incidence of this com-
plication, because unsuccessful outcomes with this ap-
proach would be less likely to be reported. It is slightly
lower than the percentage found in the only case series
identified in the literature, performed by Burks et al41 and
Danneels et al,10 who reported a re-infection or AEF
recurrence rate of 50% and 60%, respectively, for a mean
follow-up period of 17 (range, 0.87-34) and 10 (range,
0.61-31), respectively.
In the presence of such high treatment failure rates, our
analysis attempted to identify whether there are any factors
indicating poor outcome, which would possibly help find a
subgroup of such patients in whom endovascular repair is
not the best option. From the factors included in our
analysis (Table II), it was found that gender and age (70
years) do not affect the outcome. Furthermore, it was
found that secondary as compared to primary AEF had an
almost threefold increased risk of persistent/recurrent in-
fection, though it did not reach statistical significance. This
may be explained by the presence of a prosthetic material
from the previous aortic reconstructive surgery, which re-
mains in communication with the gut flora and acts as a
nidus that perpetuates the infection. The site of the in-
volved part of the gastrointestinal tract does not seem to
affect the outcome, even though it could be expected that
different types and concentrations of bacteria would have
variable impact on the infectious process associated with
the AEF. However, it was found that thoracic aortic as
compared with abdominal aortic AEF were nine times
more likely to be primary than secondary, which reached
statistical significance (P  .001). This might be explained
by the higher incidence of esophageal carcinoma invading
the thoracic aorta than abdominal gastrointestinal carci-
noma invading the aorta, the higher incidence of ingested
foreign bodies eroding the esophagus than lower parts of
the gastrointestinal tract, and the higher incidence of re-
paired abdominal aortic aneurysm than thoracic aortic an-
eurysm. In terms of the mode of presentation, our analysis
found that the presence of hemodynamic instability preop-
eratively does not significantly influence outcome, whereas
clinical, laboratory, or imaging signs of infection preoper-
atively were found as strong factors indicating poor out-
come (P  .05). In the present analysis, the attempts to
interrupt the communication between the aortic and bowel
lumenwith either minimally invasive (endoscopic or endovas-
cular) or surgical methods did not achieve eradication of the
source of infection (Table II), even though one report34 of
endoscopic injection of fibrin sealant and another37 of intra-
vascular occlusion of the fistula tract presented good short-
term results. Additionally, life-long antibiotic therapy did
not achieve better outcome in the prevention of sepsis.
Nevertheless, life-long antibiotics may still be useful, since
the sicker patients with worse infections were probably
maintained on antibiotics for longer periods than patients
without signs of infection. The fact that 30% of patients
who did not have evidence of infection preoperatively
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the presumption by the respective authors that a foreign
material was placed in a potentially infected field, commu-
nicating with the gastrointestinal tract.
Our analysis has also shown that the persistent/recurrent/
new infection group developed a statistically significant
higher complication rate (94.44% vs 17.29%; OR, 80.750;
95% CI, 8.203-794.944). Most complications were related
to sepsis or recurrent bleeding developed in the period
from the AEF repair up to the end of follow-up for each
individual patient. Furthermore, survival analysis found
that the persistent/recurrent infection group had statisti-
cally significant shorter 30-day and overall survival (Fig). As
shown in Table I, most deaths were associated with septic
or hemorrhagic complications of the AEF, which under-
scores the importance of the prevention of continuing
contamination.
The lack of uniform reporting results in difficulties to
uniformly categorize the cases in respect to preoperative
hemodynamic status, severity of bleeding and infection, as
well as the length and type of antibiotic therapy. We at-
tempted to set the definitions in order to proceed with the
analysis of the various factors involved. Therefore, because
of these weaknesses our results should be assessed with
caution. In this systematic review, no comparison of the
results after endovascular stent graft repair of AEF with
those after conventional open surgical repair was under-
taken. Because randomizedmulti-center studies comparing
the outcome of endovascular with that of open repair in
such an acute condition is difficult, a further systematic
review to compare both methods would be an interesting
undertaking.
CONCLUSIONS
Endovascular stent graft repair of AEF is associated
with a high incidence of persistent/recurrent/new infec-
tion or recurrent bleeding. Our analysis has revealed that
evidence of infection preoperatively is a factor associated
with poor outcome after endovascular repair. Therefore, it
appears that at least for this subgroup of patients, endovas-
cular repair should be considered a bridge to more defini-
tive repair at a later time, after the optimization of the
patients’ condition. However, this requires further indica-
tion from other studies.
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